Valuation Metrics and Financial Performance
Star Imaging currently trades at a price-to-earnings (PE) ratio of approximately 13.8, which is notably lower than many of its healthcare sector peers. Its price-to-book value stands at 4.66, indicating that the market values the company at nearly five times its net asset value. The enterprise value to EBITDA ratio of 8.67 further suggests a moderate valuation relative to earnings before interest, tax, depreciation, and amortisation. These multiples place Star Imaging in the ‘expensive’ category, a downgrade from its previous ‘very expensive’ status as of early December 2025.
Importantly, Star Imaging boasts a strong return on capital employed (ROCE) of 31.55% and a return on equity (ROE) of 33.81%, signalling efficient use of capital and shareholder funds. These profitability metrics are well above average for the healthcare services industry, underscoring the company’s operational strength and competitive positioning.
Peer Comparison Highlights
When compared with its peers, Star Imaging’s valuation appears more reasonable. Several competitors such as Max Healthcare, Fortis Healthcare, and Dr Agarwal’s Healthcare are classified as ‘very expensive’ with PE ratios often exceeding 40 and EV/EBITDA multiples above 30. In contrast, Star Imaging’s more modest multiples suggest it is relatively undervalued within its sector, despite being labelled ‘expensive’ overall.
Apollo Hospitals stands out as ‘attractive’ with higher valuation multiples but also a PEG ratio above 1, indicating expectations of growth. Star Imaging’s PEG ratio is zero, which may reflect either a lack of projected earnings growth or insufficient data, warranting cautious interpretation.
From struggle to strength! This Small Cap from Textile - Machinery is showing early turnaround signals that look promising. Position yourself now for explosive growth potential ahead!
- - Early turnaround signals
- - Explosive growth potential
- - Textile - Machinery recovery play
Position for Explosive Growth →
Stock Price Performance and Market Sentiment
Star Imaging’s share price has experienced a recent decline, with a one-week return of -6.67% and a one-month return of -14.81%, both underperforming the Sensex benchmark, which gained 0.59% and 1.34% respectively over the same periods. The stock currently trades near its 52-week low of ₹123, compared to a high of ₹152, indicating some market caution or profit-taking.
This underperformance relative to the broader market may reflect investor concerns about growth prospects or sector-specific challenges. However, the company’s strong profitability ratios and relatively moderate valuation multiples suggest that the market may be overly pessimistic, potentially creating a buying opportunity for value-oriented investors.
Balancing Valuation and Growth Prospects
While Star Imaging is classified as ‘expensive’, it is far from the stretched valuations seen in many of its healthcare peers. Its solid ROCE and ROE indicate that the company is generating substantial returns on invested capital, which can justify a premium valuation. However, the absence of a meaningful PEG ratio and recent price weakness highlight the need for investors to carefully consider growth prospects and sector dynamics before committing capital.
Investors should also weigh the company’s valuation against broader market conditions and healthcare industry trends. Given the company’s current multiples and profitability, Star Imaging appears fairly valued to slightly undervalued relative to its intrinsic worth and peer group, especially when factoring in its operational efficiency.
Conclusion: Is Star Imaging Overvalued or Undervalued?
In summary, Star Imaging’s valuation has moderated from very expensive to expensive, reflecting a more balanced market view. Its valuation multiples are reasonable compared to many healthcare peers, and its strong returns on capital support a premium rating. Despite recent share price declines and underperformance against the Sensex, the company’s fundamentals suggest it is not overvalued.
For investors seeking exposure to the healthcare services sector, Star Imaging offers a compelling blend of solid profitability and moderate valuation. While not a bargain basement stock, it is arguably undervalued relative to its peer group’s stretched multiples and may represent a prudent investment for those prioritising quality and value.
As always, investors should conduct thorough due diligence, considering both company-specific factors and broader market conditions before making investment decisions.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
